Enanta Pharmaceuticals to Present at the H.C. Wainwright 2nd Annual Hepatitis B Virus Virtual Conference
October 05 2021 - 7:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
for viral infections and liver diseases, today announced that Jay
R. Luly, Ph.D., President and Chief Executive Officer, will
participate in a fireside chat on Wednesday, October 13, 2021, at
3:30 p.m. ET at the H.C. Wainwright 2nd Annual Hepatitis B Virus
Virtual Conference.
A live webcast of the event will be accessible by visiting the
“Events and Presentations” section on the “Investors” page of
Enanta’s website at www.enanta.com. Replays of the webcasts will be
available following the presentations and will be archived for at
least 30 days.
About Enanta Enanta is using its robust, chemistry-driven
approach and drug discovery capabilities to become a leader in the
discovery and development of small molecule drugs for the treatment
of viral infections and liver diseases. Enanta’s research and
development efforts have produced clinical candidates currently in
development for the following disease targets: respiratory
syncytial virus (RSV), hepatitis B virus (HBV) and SARS-CoV-2
(COVID-19). Enanta is also conducting research in human
metapneumovirus (hMPV).
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is sold by AbbVie in numerous countries as
part of its leading treatment for chronic HCV infection under the
tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.)
(glecaprevir/pibrentasvir). Please visit www.enanta.com for more
information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211005005361/en/
Media and Investors Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jul 2023 to Jul 2024